Literature DB >> 35950385

[Correlation between metabolic syndrome and prognosis of patients with clear cell renal cell carcinoma].

M N Zuo1, Y Q DU1, L P Yu1, X Dai1, T Xu1.   

Abstract

OBJECTIVE: To investigate the effects of MetS on the prognosis of patients with clear cell renal cell carcinoma (ccRCC).
METHODS: Clinical and pathological data and the laboratory test of ccRCC 342 patients with diverticular stones who underwent ccRCC who underwent radical or partial nephrectomy were retrospectively collected and analyzed.The patients were divided into MetS group and non-MetS group, and the subgroups were defined according to the tumor size. The overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) of the two groups were analyzed by univariate Cox analysis, and the subgroup analyses were also performed. Kaplan-Meier survival curve and survival analysis for OS, CSS, and PFS of the two groups and the subgroups were conducted.
RESULTS: Univariate Cox analysis showed that MetS was a protective factor of postoperative OS [hazard ratio (HR)=0.551, 95%CI: 0.321-0.949, P=0.031], CSS (HR=0.460, 95%CI: 0.234-0.905, P=0.025), and PFS (HR 0.585, 95%CI: 0.343-0.998, P=0.049) in the patients with ccRCC. In the subgroup with tumor size≤4 cm, MetS was not associated with postoperative OS (HR=0.857, 95%CI: 0.389-1.890, P=0.702), CSS (HR=1.129, 95%CI: 0.364-3.502, P=0.833), and PFS (HR=1.554, 95%CI: 0.625-3.864, P=0.343). In the subgroup with tumor size>4 cm, Mets was a protective factor of postoperative OS (HR=0.377, 95%CI: 0.175-0.812, P=0.013), CSS (HR=0.280, 95%CI: 0.113-0.690, P=0.006), and PFS (HR=0.332, 95%CI: 0.157-0.659, P=0.002); Obesity was a protective factor of postoperative CSS (HR=0.464, 95%CI: 0.219-0.981, P=0.044), and PFS (HR=0.445, 95%CI: 0.238-0.833, P=0.011). Kaplan-Meier survival analysis showed that the long-term survival of patients with MetS was better than those without MetS in OS (P=0.029), CSS (P=0.021), and PFS (P=0.046); for the subgroup with tumor size≤4 cm, there was no significant difference in postoperative OS (P=0.702), CSS (P=0.833), and PFS (P=0.339) between patients with and without MetS; For the subgroup with tumor size>4 cm, the OS (P=0.010), CSS (P=0.003), and PFS (P=0.001) of patients with MetS were better than those without MetS.
CONCLUSION: MetS was a protective factor of postoperative OS, CSS, and PFS in the patients with ccRCC, which was more obvious in subgroup with tumor size>4 cm. And obesity, the component of MetS, was correlated with postoperative OS and CSS.

Entities:  

Keywords:  Cancer-specific survival; Clear cell renal cell carcinoma; Metabolic syndrome; Overall survival; Progression-free survival

Mesh:

Year:  2022        PMID: 35950385      PMCID: PMC9385524     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  25 in total

Review 1.  Metformin in cancer.

Authors:  Ritwika Mallik; Tahseen A Chowdhury
Journal:  Diabetes Res Clin Pract       Date:  2018-05-26       Impact factor: 5.602

2.  Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.

Authors:  Earl S Ford
Journal:  Diabetes Care       Date:  2005-11       Impact factor: 19.112

3.  Effect of obesity on prognosis after early-stage breast cancer.

Authors:  Marianne Ewertz; Maj-Britt Jensen; Katrín Á Gunnarsdóttir; Inger Højris; Erik H Jakobsen; Dorte Nielsen; Lars E Stenbygaard; Ulla B Tange; Søren Cold
Journal:  J Clin Oncol       Date:  2010-11-29       Impact factor: 44.544

4.  Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma.

Authors:  Alexander S Parker; Christine M Lohse; John C Cheville; David D Thiel; Bradley C Leibovich; Michael L Blute
Journal:  Urology       Date:  2006-10       Impact factor: 2.649

5.  Effects of metabolic syndrome on renal function after radical nephrectomy in patients with renal cell carcinoma.

Authors:  Yong Zhang; Tingkun Wu; Jingjing Xie; Liqun Yan; Xiuli Guo; Weijia Xu; Liping Wang
Journal:  Int Urol Nephrol       Date:  2021-01-18       Impact factor: 2.370

6.  Effect of Metabolic Syndrome and Individual Components on Colon Cancer Characteristics and Prognosis.

Authors:  Ana Silva; Sofia S Pereira; Mariana P Monteiro; António Araújo; Gil Faria
Journal:  Front Oncol       Date:  2021-03-04       Impact factor: 6.244

Review 7.  The Role of Aberrant Metabolism in Cancer: Insights Into the Interplay Between Cell Metabolic Reprogramming, Metabolic Syndrome, and Cancer.

Authors:  Yina Yu; Liang Gong; Jun Ye
Journal:  Front Oncol       Date:  2020-06-11       Impact factor: 6.244

Review 8.  PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review).

Authors:  Daniela Miricescu; Daniela Gabriela Balan; Adrian Tulin; Ovidiu Stiru; Ileana Adela Vacaroiu; Doina Andrada Mihai; Cristian Constantin Popa; Raluca Ioana Papacocea; Mihaly Enyedi; Nedelea Andrei Sorin; Guenadiy Vatachki; Dragoș Eugen Georgescu; Adriana Elena Nica; Constantin Stefani
Journal:  Exp Ther Med       Date:  2021-03-23       Impact factor: 2.447

9.  Prevalence and Influencing Factors of Metabolic Syndrome among Adults in China from 2015 to 2017.

Authors:  Fan Yao; Yacong Bo; Liyun Zhao; Yaru Li; Lahong Ju; Hongyun Fang; Wei Piao; Dongmei Yu; Xiangqian Lao
Journal:  Nutrients       Date:  2021-12-15       Impact factor: 5.717

10.  Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma.

Authors:  Stefano Luzzago; Carlotta Palumbo; Giuseppe Rosiello; Angela Pecoraro; Marina Deuker; Franziska Stolzenbach; Francesco Alessandro Mistretta; Zhe Tian; Gennaro Musi; Emanuele Montanari; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Ottavio de Cobelli; Pierre I Karakiewicz
Journal:  Urology       Date:  2020-03-06       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.